COGT Cogent Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COGT

Price (delayed)

$8.20

Market cap

$314.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.98

Enterprise value

$87.69M

Sector: Healthcare
Industry: Biotechnology

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed ...

Highlights

Cogent Biosciences's quick ratio has soared by 51% from the previous quarter
The company's debt fell by 16% YoY and by 9% QoQ
The revenue has shrunk by 97% YoY and by 89% QoQ
The gross profit has dropped by 97% year-on-year and by 89% since the previous quarter

Key stats

What are the main financial stats of COGT
Market
Shares outstanding
38.41M
Market cap
$314.96M
Enterprise value
$87.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.34
Price to sales (P/S)
340.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
104.4
Earnings
Revenue
$840,000
EBIT
-$184.84M
EBITDA
-$184.4M
Free cash flow
-$39M
Per share
EPS
-$14.98
Free cash flow per share
-$1.12
Book value per share
$6.1
Revenue per share
$0.02
TBVPS
$6.81
Balance sheet
Total assets
$237.61M
Total liabilities
$10.85M
Debt
$4.72M
Equity
$226.76M
Working capital
$223.83M
Liquidity
Debt to equity
0.02
Current ratio
28.16
Quick ratio
28.15
Net debt/EBITDA
1.23
Margins
EBITDA margin
-21,952.4%
Gross margin
100%
Net margin
-22,005%
Operating margin
-10,578.3%
Efficiency
Return on assets
-112.1%
Return on equity
-161.3%
Return on invested capital
-39,644.4%
Return on capital employed
-80.6%
Return on sales
-22,005%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COGT stock price

How has the Cogent Biosciences stock price performed over time
Intraday
2.24%
1 week
4.19%
1 month
-3.53%
1 year
1,418.52%
YTD
-26.98%
QTD
-6.61%

Financial performance

How have Cogent Biosciences's revenue and profit performed over time
Revenue
$840,000
Gross profit
$840,000
Operating income
-$88.86M
Net income
-$184.84M
Gross margin
100%
Net margin
-22,005%
The revenue has shrunk by 97% YoY and by 89% QoQ
The gross profit has dropped by 97% year-on-year and by 89% since the previous quarter
COGT's operating income is down by 8% since the previous quarter
The company's net income fell by 3.1% QoQ

Growth

What is Cogent Biosciences's growth rate over time

Valuation

What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
1.34
P/S
340.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
104.4
The EPS rose by 7% QoQ
The company's equity fell by 3.4% QoQ
The revenue has shrunk by 97% YoY and by 89% QoQ

Efficiency

How efficient is Cogent Biosciences business performance
COGT's return on invested capital has dropped by 135% since the previous quarter
The ROA has plunged by 130% YoY but it has grown by 28% from the previous quarter
The company's return on equity has shrunk by 93% YoY but it rose by 42% QoQ

Dividends

What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COGT.

Financial health

How did Cogent Biosciences financials performed over time
COGT's current ratio has surged by 51% since the previous quarter
Cogent Biosciences's quick ratio has soared by 51% from the previous quarter
The company's debt is 98% lower than its equity
Cogent Biosciences's debt to equity has shrunk by 91% YoY
The company's debt fell by 16% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.